Disparities in Genetic Testing and Care Among Black Women with Hereditary Breast Cancer

Overview

Journal Curr Breast Cancer Rep

Date 2021 Feb 19

PMID 33603954

Citations 22

Authors

Sonya Reid

Sydney Cadiz

Tuya Pal

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Despite a steady improvement in breast cancer survival rates over the past several decades, mortality disparities remain among Black women, who have a 42% higher death rate compared to non-Hispanic white (NHW) women. Hereditary breast cancer (HBC) accounts for 5-10% of all breast cancer cases, the majority of which are due to the and () genes. Despite the availability of testing for over 25 years, there remain disproportionately lower rates of genetic testing among Blacks compared to NHW due to a multitude of factors. The intent of this review is to discuss racial disparities focused on HBC across diverse populations and review the existing gaps to be addressed when delivering gene-based care.

Recent Findings: The factors contributing to the racial survival disparity are undoubtedly complex and likely an interplay between tumor biology, genomics, patterns of care and socioeconomic factors. Advances in genomic technologies that now allow for full characterization of germline DNA sequencing are integral in defining the complex and multifactorial cause of breast cancer and may help to explain the existing racial survival disparities.

Summary: Identification of inherited cancer risk may lead to cancer prevention, early cancer detection, treatment guidance, and ultimately has great potential to improve outcomes. Consequently, advances in HBC diagnosis and treatment without widespread implementation have the potential to further widen the existing breast cancer mortality gap between Black and NHW women.

Citing Articles

Reclassification of variants of uncertain significance by race, ethnicity, and ancestry for patients at risk for breast cancer.

Pleasant V, Boggan J, Richards B, Milliron K, Purrington K, Simon M Front Oncol. 2025; 15:1455509.

PMID: 40040729 PMC: 11876048. DOI: 10.3389/fonc.2025.1455509.

Using the Translational Science Benefits Model to assess the impact of the Penn Implementation Science Center in Cancer Control.

Schnoll R, Bekelman J, Blumenthal D, Asch D, Buttenheim A, Chaiyachati K J Clin Transl Sci. 2024; 8(1):e166.

PMID: 39619072 PMC: 11604509. DOI: 10.1017/cts.2024.554.

Engaging communities: A scoping literature review of community-based participatory research in genetics service delivery settings.

Zierhut H, Kandikonda P, Simon E, Donarski C, Kocher M, Ramirez M J Community Genet. 2024; 15(6):583-602.

PMID: 39586936 PMC: 11645335. DOI: 10.1007/s12687-024-00740-9.

Disparities in Genetic Testing for Inborn Errors of Immunity.

Gilbert K, McLaughlin H, Farmer J, Ong M J Allergy Clin Immunol Pract. 2024; 13(2):388-395.e3.

PMID: 39579980 PMC: 11807750. DOI: 10.1016/j.jaip.2024.11.011.

Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.

Meernik C, Wang F, Raveendran Y, Green M, Check D, Bosworth H Cancer Res Commun. 2024; 4(11):2968-2975.

PMID: 39440958 PMC: 11570879. DOI: 10.1158/2767-9764.CRC-24-0134.

References

. Statement of the American Society of Clinical Oncology: genetic testing for cancer susceptibility, Adopted on February 20, 1996. J Clin Oncol. 1996; 14(5):1730-6; discussion 1737-40. DOI: 10.1200/JCO.1996.14.5.1730. View

Petrovski S, Goldstein D . Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. Genome Biol. 2016; 17(1):157. PMC: 4944427. DOI: 10.1186/s13059-016-1016-y. View

Finch A, Lubinski J, Moller P, Singer C, Karlan B, Senter L . Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol. 2014; 32(15):1547-53. PMC: 4026578. DOI: 10.1200/JCO.2013.53.2820. View

Kaplan C, Haas J, Perez-Stable E, Gregorich S, Somkin C, Des Jarlais G . Breast cancer risk reduction options: awareness, discussion, and use among women from four ethnic groups. Cancer Epidemiol Biomarkers Prev. 2006; 15(1):162-6. DOI: 10.1158/1055-9965.EPI-04-0758. View

Robson M, Im S, Senkus E, Xu B, Domchek S, Masuda N . Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017; 377(6):523-533. DOI: 10.1056/NEJMoa1706450. View

Zheng Y, Walsh T, Gulsuner S, Casadei S, Lee M, Ogundiran T . Inherited Breast Cancer in Nigerian Women. J Clin Oncol. 2018; 36(28):2820-2825. PMC: 6161833. DOI: 10.1200/JCO.2018.78.3977. View

Conley C, Ketcher D, Reblin M, Kasting M, Cragun D, Kim J . The big reveal: Family disclosure patterns of BRCA genetic test results among young Black women with invasive breast cancer. J Genet Couns. 2020; 29(3):410-422. PMC: 7343233. DOI: 10.1002/jgc4.1196. View

Daly B, Olopade O . A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change. CA Cancer J Clin. 2015; 65(3):221-38. DOI: 10.3322/caac.21271. View

Randall T, Armstrong K . Health Care Disparities in Hereditary Ovarian Cancer: Are We Reaching the Underserved Population?. Curr Treat Options Oncol. 2016; 17(8):39. DOI: 10.1007/s11864-016-0417-1. View

10.

Menes T, Terry M, Goldgar D, Andrulis I, Knight J, John E . Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2015; 151(3):653-60. PMC: 4545282. DOI: 10.1007/s10549-015-3419-y. View

11.

Newman L . Breast cancer in African-American women. Oncologist. 2005; 10(1):1-14. DOI: 10.1634/theoncologist.10-1-1. View

12.

Young S, Pilarski R, Donenberg T, Shapiro C, Hammond L, Miller J . The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer. 2009; 9:86. PMC: 2666759. DOI: 10.1186/1471-2407-9-86. View

13.

McCarthy A, Yang J, Armstrong K . Increasing disparities in breast cancer mortality from 1979 to 2010 for US black women aged 20 to 49 years. Am J Public Health. 2015; 105 Suppl 3:S446-8. PMC: 4455497. DOI: 10.2105/AJPH.2014.302297. View

14.

Middha Kapoor P, Lindstrom S, Behrens S, Wang X, Michailidou K, Bolla M . Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. Int J Epidemiol. 2019; 49(1):216-232. PMC: 7426027. DOI: 10.1093/ije/dyz193. View

15.

Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A . Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol. 1999; 22(5):436-40. DOI: 10.1097/00000421-199910000-00002. View

16.

Pierce L, Phillips K, Griffith K, Buys S, Gaffney D, Moran M . Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy. Breast Cancer Res Treat. 2010; 121(2):389-98. PMC: 2936479. DOI: 10.1007/s10549-010-0894-z. View

17.

Jagsi R, Griffith K, Kurian A, Morrow M, Hamilton A, Graff J . Concerns about cancer risk and experiences with genetic testing in a diverse population of patients with breast cancer. J Clin Oncol. 2015; 33(14):1584-91. PMC: 4417728. DOI: 10.1200/JCO.2014.58.5885. View

18.

Katz S, Ward K, Hamilton A, McLeod M, Wallner L, Morrow M . Gaps in Receipt of Clinically Indicated Genetic Counseling After Diagnosis of Breast Cancer. J Clin Oncol. 2018; 36(12):1218-1224. PMC: 5908222. DOI: 10.1200/JCO.2017.76.2369. View

19.

Owens D, Davidson K, Krist A, Barry M, Cabana M, Caughey A . Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2019; 322(7):652-665. DOI: 10.1001/jama.2019.10987. View

20.

Sorlie T, Tibshirani R, Parker J, Hastie T, Marron J, Nobel A . Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003; 100(14):8418-23. PMC: 166244. DOI: 10.1073/pnas.0932692100. View